Literature DB >> 25400231

Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone?

Stephen J Simko1, Kenneth L McClain, Carl E Allen.   

Abstract

Entities:  

Keywords:  Langerhans cell histiocytosis; cytarabine; prednisone; vinblastine

Mesh：

Substances：

Year:  2014        PMID： 25400231      PMCID： PMC4791956          DOI： 10.1111/bjh.13208

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.

Authors:  Helmut Gadner; Milen Minkov; Nicole Grois; Ulrike Pötschger; Elfriede Thiem; Maurizio Aricò; Itziar Astigarraga; Jorge Braier; Jean Donadieu; Jan-Inge Henter; Gritta Janka-Schaub; Kenneth L McClain; Sheila Weitzman; Kevin Windebank; Stephan Ladisch
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

2.  Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution.

Authors:  R M Egeler; J de Kraker; P A Voûte
Journal:  Med Pediatr Oncol       Date:  1993

3.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Authors:  Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen
Journal:  J Exp Med       Date:  2014-03-17       Impact factor: 14.307

4.  Optimal therapy for adults with Langerhans cell histiocytosis bone lesions.

Authors:  Maria A Cantu; Philip J Lupo; Mrinalini Bilgi; M John Hicks; Carl E Allen; Kenneth L McClain
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240
  4 in total
  8 in total

1.  How I treat Langerhans cell histiocytosis.

Authors:  Carl E Allen; Stephan Ladisch; Kenneth L McClain
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

Review 2.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

3.  Treatment of Langerhans cell histiocytosis: it is time to learn from the past: response to Minkov and Rodriguez-Galindo.

Authors:  Carl E Allen; Kenneth L McClain
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

Review 4.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

5.  Management of severe pulmonary Langerhans cell histiocytosis in children.

Authors:  Olive S Eckstein; Jed G Nuchtern; George B Mallory; R Paul Guillerman; Matthew A Musick; Mhairi Barclay; Jayesh M Bhatt; Patrick Davies; Richard G Grundy; Alice Martin; Tom Hilliard; Stephen P Lowis; Susan Picton; Vasanta Nanduri; Johannes Visser; Carl E Allen; Kenneth L McClain
Journal:  Pediatr Pulmonol       Date:  2020-06-08

Review 6.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

7.  Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.

Authors:  Xue Tang; Ju Gao; Zhi-Gui Ma; Xia Guo; Qiang Li; Zhi Wan; Jing-Jing Sun
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

Review 8.  Current perspectives on the role of liver transplantation for Langerhans cell histiocytosis: A narrative review.

Authors:  Jagadeesh Menon; Ashwin Rammohan; Mukul Vij; Naresh Shanmugam; Mohamed Rela
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.